Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 4
2005 4
2006 6
2007 17
2008 22
2009 23
2010 11
2011 9
2012 12
2013 20
2014 19
2015 15
2016 20
2017 17
2018 25
2019 24
2020 26
2021 39
2022 23
2023 26
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

332 results

Results by year

Filters applied: . Clear all
Page 1
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study.
Decaux O, Fontan J, Perrot A, Karlin L, Touzeau C, Schulmann S, Manier S, Belhadj K, Trebouet A, Zunic P, Schiano De Colella JM, Castel B, Van De Wyngaert Z, Pica GM, Tiab M, Kuhnowski F, Bouketouche M, Rigaudeau S, Benramdane R, Tekle C, Lafore R, Gaucher M, Corre J, Leleu X. Decaux O, et al. Among authors: leleu x. Eur J Haematol. 2024 May 7. doi: 10.1111/ejh.14225. Online ahead of print. Eur J Haematol. 2024. PMID: 38712850
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, Pérez-Larraya JG, Manier S, Nooka AK, Mateos MV, Einsele H, Minnema M, Cavo M, Derman BA, Puig N, Gay F, Ho PJ, Chng WJ, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje NS, Zamagni E, Hájek R, Weinhold N, Yong K, Ye JC, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman JL; International Myeloma Working Group. Rodriguez-Otero P, et al. Among authors: leleu x. Lancet Oncol. 2024 May;25(5):e205-e216. doi: 10.1016/S1470-2045(24)00043-3. Lancet Oncol. 2024. PMID: 38697166 Review.
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial.
Mateos MV, Engelhardt M, Leleu X, Mesa MG, Cavo M, Dimopoulos M, Bianco M, Merlo GM, Porte C, Richardson PG, Moreau P. Mateos MV, et al. Among authors: leleu x. Eur J Haematol. 2024 May 1. doi: 10.1111/ejh.14223. Online ahead of print. Eur J Haematol. 2024. PMID: 38693052
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Lee HC, Ramasamy K, Macro M, Davies FE, Abonour R, van Rhee F, Hungria VTM, Puig N, Ren K, Silar J, Enwemadu V, Cherepanov D, Leleu X. Lee HC, et al. Among authors: leleu x. Eur J Haematol. 2024 Apr 23. doi: 10.1111/ejh.14214. Online ahead of print. Eur J Haematol. 2024. PMID: 38654611
RAS/RAFlandscape in monoclonal plasma cell conditions.
Schavgoulidze A, Corre J, Samur MK, Mazzotti C, Pavageau L, Perrot A, Cazaubiel T, Leleu X, Macro M Dr, Belhadj K, Roussel M, Brechignac S, Montes L Jr, Caillot D, Frenzel L, Rey P, Schiano JM, Chalopin T, Jacquet C, Richez V, Orsini Piocelle F, Fontan J, Manier S, Martinet L, Sciambi A, Mohty M, Avet-Loiseau H. Schavgoulidze A, et al. Among authors: leleu x. Blood. 2024 Apr 21:blood.2023022295. doi: 10.1182/blood.2023022295. Online ahead of print. Blood. 2024. PMID: 38643494
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Garderet L, Gras L, Koster L, De Wreede L, Montserrat R, Vincent L, Fenk R, Karunanithi K, Deeren D, Kaufmann M, Kuball J, Ozdogu H, Cascon MJP, Passweg J, Rye A, Salmenniemi U, Snowden J, Hansen CT, Leleu X, Gastaud L, Sokolowska JD, Raj K, Beksac M, Schönland S, Hayden P, McLornan D. Garderet L, et al. Among authors: leleu x. Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2023.284520. Online ahead of print. Haematologica. 2024. PMID: 38546696 Free article.
Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study.
Laribi K, Leleu X, Texier N, Germain R, Touzeau C, Hammoud M, Payssot A, Schulmann S, Le Calloch R, Trebouet A, Chaoui D, David S, Benbrahim O, Benramdane R, Charvet-Rumpler A, Jadeau C, Rouanet E, Decaux O, Perrot A. Laribi K, et al. Among authors: leleu x. EJHaem. 2023 Dec 13;5(1):55-60. doi: 10.1002/jha2.828. eCollection 2024 Feb. EJHaem. 2023. PMID: 38406520 Free PMC article.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Mateos MV, Weisel K, Terpos E, Delimpasi S, Kastritis E, Zamagni E, Delforge M, Ocio E, Katodritou E, Gay F, Larocca A, Leleu X, Otero PR, Schjesvold F, Cavo M, Dimopoulos MA. Mateos MV, et al. Among authors: leleu x. Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284694. Online ahead of print. Haematologica. 2024. PMID: 38385280 Free article.
332 results